Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy
jRCT1080225004Recruiting
- Sponsor
- Novartis
- Start
- Jan 2020
01
Overview
Open-label, single-arm trial in hematopoietic malignancies and Nonhematologic neoplasms, sponsored by Novartis. Primary endpoint: Long-term safety and outcomes after lentiviral-based CAR T-cell therapy. Started Jan 2020; status: recruiting.
02
Conditions
hematopoietic malignanciesNonhematologic neoplasms
Beyond the preview
Go deeper on jRCT1080225004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080225004.